Case Summary

Marinus Pharmaceuticals

NASDAQ: MRNS

Case Details

  • Bishins v. Marinus Pharmaceuticals, Inc. et al.
  • Class Period:March 17, 2021 - May 7, 2024
  • Date Filed:June 05, 2024
  • Jurisdiction:U.S. District Court, Eastern District of Pennsylvania
  • Docket Number: 2:24-cv-02430
  • Lead Plaintiff Deadline: August 5, 2024
Days Left to
Seek Plaintiff
41

Overview

A class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. (“Marinus” or the “Company”) (NASDAQ: MRNS) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws.  The Marinus class action lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired publicly traded Marinus securities between March 17, 2021 and May 7, 2024, both dates inclusive (the “Class Period”).  Investors have until August 5, 2024 to seek appointment as lead plaintiff of the Marinus class action lawsuit.

Marinus describes itself as a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY® (ganaxolone).

Pertinent to the class action lawsuit is the Randomized Therapy in Status Epilepticus trial (“RAISE”), which the Company has described as a “pivotal Phase 3 trial in refractory status epilepticus (RSE) patients.”

The Marinus class action lawsuit alleges that Defendants, throughout the Class Period, made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; (2) Defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, Defendants’ statements about their business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.  When the true details entered the market, the lawsuit claims that investors suffered damages.

*          *          *

If you purchased or otherwise acquired publicly traded Marinus securities between March 17, 2021 and May 7, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the Marinus lawsuit is August 5, 2024.

Join This Action

Name(Required)
Address(Required)
Are you a current or former employee at the company?(Required)

Purchases

Purchases Buy Date Quantity Purchase Price per share or security Actions
       

Sales

Sale Type Sale Date Quantity Sale Price per share or security Actions
       

Upload Documents

Drop files here or
Accepted file types: xls, xlsx, doc, pdf, jpg, jpeg, Max. file size: 50 MB, Max. files: 5.